Health Care/Hospital

Entering the New Year, VARON Strengthens Commitment to Dependable Oxygen Support

NEW YORK, Dec. 30, 2025 /PRNewswire/ -- As the new year begins, it offers a meaningful moment to reflect on shared progress and renewed responsibility in respiratory care. Over the past year, VARON has continued to focus on what matters most—rel...

2025-12-31 07:34 4554

Mabwell Announces First Patient Dosed in Phase II Trial of Anti-IL-11 Antibody for Pathological Scarring

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scar...

2025-12-30 22:00 5250

China's Sleep Technology Pioneer Sleemon Draws Increasing Interest from the Global AI Community

SHAOXING, China, Dec. 30, 2025 /PRNewswire/ -- A long-established household brand inChina with a comparatively limited international profile, Sleemon Healthy Sleep Technology Co., Ltd. is gaining attention from the global technology community as it expands its focus on advanced sleep technology ...

2025-12-30 21:54 4496

The "Eastern Wisdom" of Aging: How Taikang's "New Life Insurance" Responds to a Global Challenge?

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Under the global background of ageing people, WallstreetCN reported how TaiKang play its wisdom in new-life-insurance. In 2014, journalists from Japan's NHK documented the phenomenon of A Society Without Bonds, portraying how the elderly in an atomized soci...

2025-12-30 19:34 4067

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public ...

2025-12-30 17:00 12359

Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards

SHENZHEN, China, Dec. 29, 2025 /PRNewswire/ -- On December 5, 2025, Dr. Lu Xianping, Founder, Chairman of Shenzhen Chipscreen Biosciences Co., Ltd, has been named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards.

2025-12-30 08:45 4309

Bioelectric Toothbrush Offers New Approach with 6x Plaque Removal

Clinically validated microcurrent technology now available in the U.S. market SAN FRANCISCO, Dec. 29, 2025 /PRNewswire/ -- Great Gums Inc. today announced the U.S. launch of its bioelectric toothbrush, a clinically validated oral care device that delivers safe microcurrents to remove plaque from ...

2025-12-29 21:00 3467

HKSH Medical Group and Southern University of Science and Technology Collaborate for Medical and Medical Physics Training, Enhancing Medical Education and Research Innovation

HONG KONG, Dec. 29, 2025 /PRNewswire/ -- HKSH Medical Group ("HKSH") and Southern University of Science and Technology ("SUSTech") officially signed a Memorandum of Understanding ("MOU") on15 December 2025, a significant initiative to deepen collaboration betweenHong Kong and the Chinese Mainland...

2025-12-29 16:12 3882

Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities

SHANGHAI, Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more diverse therapeutic landscape. Viva Biotech has responded by building an integrated pharmacology pl...

2025-12-29 14:13 3038

Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE

SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...

2025-12-29 13:52 3903

Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy

TAIPEI and SAN DIEGO, Dec. 28, 2025 /PRNewswire/ -- Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the challenging field of cold tumor treatment, Senhwa Biosciences, Inc. ...

2025-12-29 10:24 2691

Assure Healthcare Holdings Opens Second Clinic in Woodlands, Singapore

SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- Assure Healthcare Holdings, a subsidiary of SingWealth Holdings, today announced the official opening of its second clinic,Assure Family Clinic Woodlands. This expansion marks the next phase in the Group's mission to make quality and comprehensive healthca...

2025-12-29 10:00 2029

Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has entered into a l...

2025-12-29 09:58 3213

Festive Season Isolation: How Eczema Is Keeping Singaporeans From Gatherings

Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period traditionally associated with connection and joy. SINGAPORE, Dec. 29, 2025 /PRNewswire/ -- For many, the festive season is marked by reunions, shared...

2025-12-29 08:30 2409

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administr...

2025-12-29 08:10 2780

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 /PRNewswire/ -- ABL Bio (CEO Sang Ho...

2025-12-26 12:55 3229

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura'snext-generation range hoods  at LVCC - South Hall 1- Booth 30725, where the brand will demonstrate how cleaner kitchen air can make every...

2025-12-26 01:30 2403

Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula

KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach ...

2025-12-25 22:08 4668

China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

* TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. * The TABOSUN® and TYVYT® c...

2025-12-25 16:45 3107

Life-space's Patented Strain LPB27 Featured in Nature Supplement, Highlighting World-Class R&D Strength

KUALA LUMPUR, Malaysia, Dec. 25, 2025 /PRNewswire/ -- The Nature supplement highlights research exploring the potential ofLPB27 and Bifidobacterium breve 207-1 in supporting digestive and metabolic health. Both strains have already been successfully integrated into multiple Life-space products an...

2025-12-25 10:14 3739
1 ... 18192021222324 ... 857